Your browser doesn't support javascript.
ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs.
Lee, Ivan T; Nakayama, Tsuguhisa; Wu, Chien-Ting; Goltsev, Yury; Jiang, Sizun; Gall, Phillip A; Liao, Chun-Kang; Shih, Liang-Chun; Schürch, Christian M; McIlwain, David R; Chu, Pauline; Borchard, Nicole A; Zarabanda, David; Dholakia, Sachi S; Yang, Angela; Kim, Dayoung; Chen, Han; Kanie, Tomoharu; Lin, Chia-Der; Tsai, Ming-Hsui; Phillips, Katie M; Kim, Raymond; Overdevest, Jonathan B; Tyler, Matthew A; Yan, Carol H; Lin, Chih-Feng; Lin, Yi-Tsen; Bau, Da-Tian; Tsay, Gregory J; Patel, Zara M; Tsou, Yung-An; Tzankov, Alexandar; Matter, Matthias S; Tai, Chih-Jaan; Yeh, Te-Huei; Hwang, Peter H; Nolan, Garry P; Nayak, Jayakar V; Jackson, Peter K.
  • Lee IT; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Nakayama T; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Wu CT; Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
  • Goltsev Y; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Jiang S; Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, Japan.
  • Gall PA; Baxter Laboratory, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA.
  • Liao CK; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Shih LC; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Schürch CM; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • McIlwain DR; Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.
  • Chu P; Department of Otorhinolaryngology, China Medical University Hospital, Taichung, Taiwan.
  • Borchard NA; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
  • Zarabanda D; Terry Fox Cancer Research Laboratory, Translational Medicine Center, China Medical University Hospital, Taichung, Taiwan.
  • Dholakia SS; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Yang A; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Kim D; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Chen H; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Kanie T; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Lin CD; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Tsai MH; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Phillips KM; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Kim R; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Overdevest JB; Baxter Laboratory, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA.
  • Tyler MA; Department of Otorhinolaryngology, China Medical University Hospital, Taichung, Taiwan.
  • Yan CH; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
  • Lin CF; School of Medicine, China Medical University, Taichung, Taiwan.
  • Lin YT; Department of Otorhinolaryngology, China Medical University Hospital, Taichung, Taiwan.
  • Bau DT; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
  • Tsay GJ; School of Medicine, China Medical University, Taichung, Taiwan.
  • Patel ZM; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Tsou YA; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Tzankov A; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Matter MS; Department of Otolaryngology-Head and Neck Surgery, Columbia University School of Medicine, New York City, NY, USA.
  • Tai CJ; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Yeh TH; Department of Otolaryngology-Head and Neck Surgery, University of Minnesota School of Medicine, Minneapolis, MN, USA.
  • Hwang PH; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Nolan GP; Department of Otolaryngology-Head and Neck Surgery, University of California San Diego School of Medicine, San Diego, CA, USA.
  • Nayak JV; Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.
  • Jackson PK; Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.
Nat Commun ; 11(1): 5453, 2020 10 28.
Article in English | MEDLINE | ID: covidwho-894390
ABSTRACT
The coronavirus SARS-CoV-2 is the causative agent of the ongoing severe acute respiratory disease pandemic COVID-19. Tissue and cellular tropism is one key to understanding the pathogenesis of SARS-CoV-2. We investigate the expression and subcellular localization of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), within the upper (nasal) and lower (pulmonary) respiratory tracts of human donors using a diverse panel of banked tissues. Here, we report our discovery that the ACE2 receptor protein robustly localizes within the motile cilia of airway epithelial cells, which likely represents the initial or early subcellular site of SARS-CoV-2 viral entry during host respiratory transmission. We further determine whether ciliary ACE2 expression in the upper airway is influenced by patient demographics, clinical characteristics, comorbidities, or medication use, and show the first mechanistic evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) does not increase susceptibility to SARS-CoV-2 infection through enhancing the expression of ciliary ACE2 receptor. These findings are crucial to our understanding of the transmission of SARS-CoV-2 for prevention and control of this virulent pathogen.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Respiratory System / Angiotensin-Converting Enzyme Inhibitors / Gene Expression / Coronavirus Infections / Peptidyl-Dipeptidase A / Angiotensin Receptor Antagonists Type of study: Prognostic study Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-19145-6

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Respiratory System / Angiotensin-Converting Enzyme Inhibitors / Gene Expression / Coronavirus Infections / Peptidyl-Dipeptidase A / Angiotensin Receptor Antagonists Type of study: Prognostic study Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-19145-6